Search

From garage start-up to global pharma: combining strengths to advance regenerative medicine

Article describing how a strategic partnership between Global Stem Cell and Boehringer Ingelheim Animal Health has played a key role in helping the companies accelerate breakthroughs in regenerative medicine.

What to Expect from Your Vaccine | Boehringer Ingelheim US

Read more on how horse owners are encouraged to schedule a wellness exam with their veterinarians, including annual equine vaccinations.

New study results show Tradjenta® (linagliptin) reduces blood sugar in adults with type 2 diabetes at risk for kidney impairment

New affordability initiative with GoodRx for our biosimilar

Boehringer Ingelheim announces patient affordability initiative with GoodRx for biosimilar

Championing for people with all abilities

Every diverse background brings unique perspectives to our company.

Jardiance® Recommended as Preferred SGLT2 Inhibitor for Adults with Type 2 Diabetes and Established Cardiovascular Disease in American College of Cardiology Expert Consensus Decision Pathway

New Platform: Unbridle Your Potential | Boehringer Ingelheim US

Read more on the Boehringer Ingelheim brand platform: Unbridle Your Potential, aimed at providing support and leadership for the equine industry.

A Planned Safety Net for Patients in Need

Boehringer Ingelheim and Vanderbilt University Announce Partnership to Develop Novel Therapies for Psychiatric Disorders

How Simulation is Changing the Game in Biotherapeutic Drug Development

A sense of community and a love for gardening that’s lasted decades at our U.S. headquarters

Discover our longstanding love for gardening and how it started with Schatzi’s chives.

Boehringer Ingelheim Animal Health Joins Coalition Calling for Greater Broadband Access in Rural Areas

ATS Announces that BI is First Donor of COVID-19 Fund | Boehringer Ingelheim US

American Thoracic Society Announces that Boehringer Ingelheim is the first donor of its COVID‐19 Crisis Fund

She finds purpose in the saddle and pursues a passion for horses – at home and work

Cyltezo®, First Interchangeable Biosimilar to Humira®, Receives Preferred Formulary Status with Optum Rx for Commercially Insured Patients

Business Resource Groups at Boehringer Ingelheim

Business Resource Groups at Boehringer Ingelheim contribute to and help shape our company culture.

Exploring beyond boundaries for innovation in animal health

Exploring beyond boundaries by partnering with human pharma and animal health may hold the key to accelerating innovation in animal health.

Topline results from Boehringer's Phase III IPF Study

Press release announcing topline results of Boehringer Ingelheim's Phase III FIBRONEER-IPF study in indiopathic pulmonary fibrosis

Boehringer Ingelheim and Vanderbilt University Expand Partnership to Develop Novel Treatment Approaches for Cancer

How to Help Prevent Lyme Disease in Your Dog | Boehringer Ingelheim US

Click here to learn more about steps that pet owners can take to help prevent Lyme Disease in dogs.

Sustainable Development for Generations | Boehringer Ingelheim US

At BI, Sustainable Development – For Generations is about a journey. One that started in 1885 and one that we hope, and believe, will never end.

Swine

Boehringer Ingelheim and Enara Bio Enter Strategic Collaboration and Licensing Agreement to Discover Novel Shared Antigens for Cancer Immunotherapies

U.S. FDA approves supplemental New Drug Applications to include landmark data in product labels for Synjardy® (empagliflozin/metformin hydrochloride), Synjardy® XR (empagliflozin/metformin hydrochloride extended-release) and Glyxambi® (empagliflozin/linag

U.S. FDA approves supplemental New Drug Applications to include landmark data in product labels for Synjardy® (empagliflozin/metformin hydrochloride), Synjardy® XR (empagliflozin/metformin hydrochloride extended-release) and Glyxambi® (empagliflozin/linag

First Data from Boehringer Ingelheim, Anthem and HealthCore Multi-Year Study Show Gaps in Non-valvular Atrial Fibrillation Care

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers

Search

From garage start-up to global pharma: combining strengths to advance regenerative medicine

What to Expect from Your Vaccine | Boehringer Ingelheim US

New study results show Tradjenta® (linagliptin) reduces blood sugar in adults with type 2 diabetes at risk for kidney impairment

New affordability initiative with GoodRx for our biosimilar

Championing for people with all abilities

Jardiance® Recommended as Preferred SGLT2 Inhibitor for Adults with Type 2 Diabetes and Established Cardiovascular Disease in American College of Cardiology Expert Consensus Decision Pathway

New Platform: Unbridle Your Potential | Boehringer Ingelheim US

A Planned Safety Net for Patients in Need

Boehringer Ingelheim and Vanderbilt University Announce Partnership to Develop Novel Therapies for Psychiatric Disorders

How Simulation is Changing the Game in Biotherapeutic Drug Development

A sense of community and a love for gardening that’s lasted decades at our U.S. headquarters

Boehringer Ingelheim Animal Health Joins Coalition Calling for Greater Broadband Access in Rural Areas

ATS Announces that BI is First Donor of COVID-19 Fund | Boehringer Ingelheim US

She finds purpose in the saddle and pursues a passion for horses – at home and work

Cyltezo®, First Interchangeable Biosimilar to Humira®, Receives Preferred Formulary Status with Optum Rx for Commercially Insured Patients

Business Resource Groups at Boehringer Ingelheim

Exploring beyond boundaries for innovation in animal health

Topline results from Boehringer's Phase III IPF Study

Boehringer Ingelheim and Vanderbilt University Expand Partnership to Develop Novel Treatment Approaches for Cancer

How to Help Prevent Lyme Disease in Your Dog | Boehringer Ingelheim US

Sustainable Development for Generations | Boehringer Ingelheim US

Swine

Boehringer Ingelheim and Enara Bio Enter Strategic Collaboration and Licensing Agreement to Discover Novel Shared Antigens for Cancer Immunotherapies

U.S. FDA approves supplemental New Drug Applications to include landmark data in product labels for Synjardy® (empagliflozin/metformin hydrochloride), Synjardy® XR (empagliflozin/metformin hydrochloride extended-release) and Glyxambi® (empagliflozin/linag

First Data from Boehringer Ingelheim, Anthem and HealthCore Multi-Year Study Show Gaps in Non-valvular Atrial Fibrillation Care